Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2012 Apr;20(4):362-73.
doi: 10.1097/JGP.0b013e3182110563.

The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design

D P Devanand  1 , Jacobo Mintzer, Susan Schultz, David Sultzer, Danilo de la Pena, Sanjay Gupta, Sylvia Colon, Corbett Schimming, Gregory H Pelton, Howard Andrews, Bruce Levin
Affiliations
Randomized Controlled Trial

The antipsychotic discontinuation in Alzheimer disease trial: clinical rationale and study design

D P Devanand et al. Am J Geriatr Psychiatry. 2012 Apr.

Abstract

Objectives: : Research studies on the effects of discontinuing antipsychotic medications in patients with dementia have not identified specific target symptoms or response to antipsychotics prior to discontinuation. The Antipsychotic Discontinuation in Alzheimer Disease (ADAD) trial addresses these issues in a randomized, double-blind, placebo-controlled, multicenter risperidone treatment and discontinuation trial. In Phase A, AD patients with psychosis or agitation receive open treatment with risperidone for 16 weeks. Responders are randomized, double-blind, to one of three arms in Phase B: 1) continuation risperidone for the next 32 weeks, 2) risperidone for the next 16 weeks followed by placebo for 16 weeks, or 3) placebo for the next 32 weeks.

Methods: : Several design features provide unique strengths to this trial: identification of target symptoms and systematic open antipsychotic treatment with only responders randomized in the discontinuation trial, use of a single antipsychotic medication, two clinically relevant time-points for discontinuation to evaluate the impact of duration of treatment on relapse, exclusion of patients at increased risk of stroke, assessment of several affected symptom domains, and state-of-the-art approaches to assess relapse and handle dropout.

Conclusions: : This study will provide clinically relevant data on the likelihood and time to relapse, and predictors of relapse, in patients switched from risperidone to placebo after response to risperidone treatment. Given the warnings about antipsychotic use in patients with dementia, studies of this type are essential to determine the optimal duration of treatment that confers the greatest benefit to risk ratio and to improve evidence-based treatment strategies.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
Flow Sheet for Study
See this image and copyright information in PMC

References

    1. Devanand DP, Jacobs DM, Tang M-X, et al. The course of psychopathologic symptoms in mild to moderate Alzheimer’s disease. Arch Gen Psychiatry. 1997;54:257–263. - PubMed
    1. Lyketsos CG, Steinberg M, Tschanz, et al. Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry. 2000;157:708–714. - PubMed
    1. Scarmeas N, Brandt J, Blacker D, et al. Disruptive behavior as a predictor in Alzheimer disease. Arch Neurol. 2007;64(12):1755–1761. - PMC - PubMed
    1. Holm A, Michel M, Stern GA, et al. The outcomes of an inpatient treatment program for geriatric patients with dementia and dysfunctional behaviors. Gerontologist. 1999;39(6):668–676. - PubMed
    1. Rovner BW, Steele CD, Shmuely Y, et al. A randomized trial of dementia care in nursing homes. J Am Geriatr Soc. 1996;44(1):7–13. - PubMed

Publication types

MeSH terms